Shares of ImmunoGen Inc. (NASDAQ:IMGN), a biopharmaceutical company focused on developing therapies to fight cancer, advanced as much as 15% after research firm Canaccord Genuity initiated coverage on the company. ImmunoGen, Inc. (NASDAQ:IMGN) stock performance was 11.02% in last session and finished the day at $14.21. Traded volume was 2.85million shares in the last session and the average volume of the stock remained 858.46K shares. The beta of the stock remained 1.77. ImmunoGen, Inc. (NASDAQ:IMGN) insider ownership is 0.30%.

The deep freeze has taken over small cap land. It has been a long time since small caps were out of vogue but the time has come. As the great rotation of capital shifts from high risk stocks to low risk, high dividend payers, many think the end has come for any investments in small caps. OXiGENE Inc (NASDAQ:OXGN). Good news drove OXiGENE Inc (NASDAQ:OXGN) to $5.40, however the risk adverse market has taken it down to $2.59. There is a key gap fill at $2.43 that offers a very intriguing risk to reward opportunity. OXiGENE Inc (NASDAQ:OXGN) rose 9.96 percent to $2.98 Wednesday on volume of 1.37million shares. The intra-day range of the stock was $2.67 to $3.10. OXiGENE Inc (NASDAQ:OXGN) has a market capitalization of $45.40million.

Zacks restated their neutral rating on shares of BioMarin Pharmaceutical Inc (NASDAQ:BMRN) in a report issued on Tuesday, AR Network reports. They currently have a $60.00 target price on the stock. Zacks’ analyst wrote, “BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s fourth quarter 2013 loss of $0.27 per share (including stock based compensation expense) was narrower than the Zacks Consensus Estimate of a loss of $0.34. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock on Apr 16, 2014 reported a increase of 5.43% to the closing price of $61.37. Its fifty two weeks range is $53.53 -$84.25. The total market capitalization recorded $8.81billion. The overall volume in the last trading session was 2.13million shares. In its share capital, BMRN has 143.62million outstanding shares.

Celldex Therapeutics Inc. (NASDAQ:CLDX) announced that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine. On Wednesday, shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) advanced 6.99% to close the day at $14.69. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as -41.36%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly revenue growth is -46.72%.